Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J, SENTRY Trial Investigators

Open source

DOI: 10.1200/jco-26-01080
Published: 2026 Aug
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-01080,
  title = {Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.},
  author = {Bose P and Ali H and Al-Ali HK and Garcia-Gutierrez V and Grosicki S and Grudeva-Popova Z and Harrison C and Hong J and Hou HA and Kwiatek M and Loschi M and Passamonti F and Patriarca A and Podoltsev N and Rampal R and Tantravahi S and Urian LG and Chai Y and Taverna P and Mark T and Sadiq A and Rangwala R and Vachhani P and Mascarenhas J and SENTRY Trial Investigators},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-01080},
  url = {https://doi.org/10.1200/jco-26-01080}
}

RIS

TY  - JOUR
TI  - Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
AU  - Bose P
AU  - Ali H
AU  - Al-Ali HK
AU  - Garcia-Gutierrez V
AU  - Grosicki S
AU  - Grudeva-Popova Z
AU  - Harrison C
AU  - Hong J
AU  - Hou HA
AU  - Kwiatek M
AU  - Loschi M
AU  - Passamonti F
AU  - Patriarca A
AU  - Podoltsev N
AU  - Rampal R
AU  - Tantravahi S
AU  - Urian LG
AU  - Chai Y
AU  - Taverna P
AU  - Mark T
AU  - Sadiq A
AU  - Rangwala R
AU  - Vachhani P
AU  - Mascarenhas J
AU  - SENTRY Trial Investigators
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-01080
UR  - https://doi.org/10.1200/jco-26-01080
ER  -

APA

P, B., H, A., HK, A., V, G., S, G., Z, G., C, H., J, H., HA, H., M, K., M, L., F, P., A, P., N, P., R, R., S, T., LG, U., Y, C., P, T., T, M., A, S., R, R., P, V., J, M., & Investigators, S. T. (2026). Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-01080

Source records

pubmed · retrieved 2026-09-26T08:03:13.183Z